A Phase 1/2 open-label trial in Parkinson’s disease has reported feasibility and early safety for STEM-PD, a cryopreserved, off-the-shelf dopaminergic progenitor derived from human pluripotent stem cells. Eight patients received intracerebral transplants in a study led by Skåne University Hospital and Lund University. The first-year follow-up reported no serious side effects linked to the transplanted cells, and the longer-term program is positioned as a milestone for regenerative approaches seeking to replace lost dopaminergic neurons. Lead scientist Malin Parmar described the results as supporting continued development toward larger cohorts. The readout arrives as the field intensifies around allogeneic cell replacement products, where immunogenicity, manufacturing, and delivery logistics are often the decisive hurdles.